These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 15695801)
21. Does health economics have an impact on non-Hodgkin's lymphoma patients' options? Otte A Nucl Med Commun; 2008 Aug; 29(8):748-9. PubMed ID: 18753830 [No Abstract] [Full Text] [Related]
22. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287 [TBL] [Abstract][Full Text] [Related]
23. Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma. Kaminski M Cancer Biol Ther; 2007 Jul; 6(7):996-7. PubMed ID: 19358342 [No Abstract] [Full Text] [Related]
24. How and why does radioimmunotherapy work? Macklis RM Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1269-71. PubMed ID: 15275708 [No Abstract] [Full Text] [Related]
32. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. Hartmann Siantar CL; DeNardo GL; DeNardo SJ J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424 [TBL] [Abstract][Full Text] [Related]
33. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk? Otte A; Dierckx RA Nucl Med Commun; 2005 Dec; 26(12):1045-7. PubMed ID: 16264349 [No Abstract] [Full Text] [Related]
34. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378 [TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
36. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920 [TBL] [Abstract][Full Text] [Related]